Gemseki

Gemseki does not publicly name an investment committee or managing partner. It operates as a business unit of Shin Nippon Biomedical Laboratories, with no disclosed investment fund or deployment vehicle.

The firm relies on its 薬市楽座 platform, which aggregates drug seeds and technologies from academic labs, biotech companies, and research institutes across its multi-office network spanning North America, East Asia, and Israel.

Neither; Gemseki is a drug-candidate marketplace and matchmaking service embedded within a publicly listed contract research organization. It does not operate a venture fund or single-family-office capital vehicle.

Gemseki appears to facilitate licensing and partnership deals — out-licensing, in-licensing, and collaborative agreements — rather than deploying capital into funds or taking direct equity positions.

Gemseki's listings center on discovery and preclinical-stage drug candidates and research technologies. It does not publish a formal stage mandate, but the language 'drug seeds' signals an emphasis on early, pre-clinical assets.

Gemseki is a dedicated business unit of SNBL, a publicly listed Japanese pharmaceutical services and contract research organization. The unit functions as a global licensing intermediary under the parent company's corporate umbrella.

Gemseki is not a family office; its operating resources derive from SNBL, a commercial entity listed on the Tokyo Stock Exchange, rather than from private family wealth.